Create a free QxMD account to receive personalized paper recommendations, relevant to your practice.

Get Started

LETTER

Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement

Jiri Minarik, Vlastimil Scudla, Tomas Tichy, Tomas Pika, Jaroslav Bacovsky, Pavel Lochman, Josef Zadrazil

Leukemia & Lymphoma 2012, 53 (2): 330-1

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

You are not logged in. Sign Up or Log In to join the discussion.

Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease. Agostina Siniscalchi, Teresa Dentamaro, Alessio Perrotti, Paola Tatangelo, Paolo de Fabritiis, Tommaso Caravita Annals of Hematology 2010, 89 (8): 821-2

Managing light chain deposition disease. Morie A Gertz Leukemia & Lymphoma 2012, 53 (2): 183-4

Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Abdul Qayum, Aamer Aleem, Abdel Rehman Al Diab, Faraz Niaz, Abdel Karim Al Momen Saudi Journal of Kidney Diseases and Transplantation 2010, 21 (1): 63-8

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Z Kaposztas, B D Kahan, S M Katz, C T Van Buren, L Cherem Transplantation Proceedings 2009, 41 (10): 4407-10

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. I Hrusovsky, B Emmerich, A von Rohr, J Voegeli, C Taverna, R A Olie, H Pliskat, C Frohn, G Hess Oncology 2010, 79 (3-4): 247-54

Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma. Giuseppe Mele, Salvatore Pinna, Emilia Alloro, Maurizio Claudio Brocca, Maria Rosaria Coppi, Giovanni Quarta Leukemia Research 2007, 31 (5): 721-3

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. Zhen-gang Yuan, Xiao-yi Dun, Yong-hua Li, Jian Hou Journal of Hematology & Oncology 2009, 2: 19

[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure]. Tsuyoshi Muta, Hideyuki Nakanishi, Megumi Yasunaga, Shozo Senba, Hiromichi Murakami, Shin Kan, Yoko Ueda, Tomoaki Fujisaki Gan to Kagaku Ryoho. Cancer & Chemotherapy 2011, 38 (2): 237-41

Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. Petr Szturz, Zdeněk Adam, Vladimír Vašků, Josef Feit, Marta Krejčí, Luděk Pour, Roman Hájek, Jiří Mayer Leukemia & Lymphoma 2013, 54 (6): 1324-6

Make the most of Read.
Download the mobile app.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read